What does the future of cancer care look like? From replacing IV chemo with oral agents to game-changing advances in bispecific and trispecific therapies, this special bonus episode dives deep into the most exciting—and practice-changing—developments from the 2025 ASCO Annual Meeting.
NCODA’s Kelly Brunk, PharmD, BCOP, returns from ASCO energized and ready to share his top takeaways in a candid conversation about where oncology is headed. Whether you're a clinician, pharmacist, or anyone in the cancer care ecosystem, this episode is packed with insight you don't want to miss.
Bonus: Kelly also shares updates on NCODA’s new Immunotherapy Hub and offers a forward-looking take on where the field is headed.
"The rate of change in oncology care is accelerating—and it's time for practices to be ready, not reactive." — Kelly Brunk
Inside the Episode:
Listen now and explore what these developments mean for clinical practice—and for the patients at the center of it all.
Resources mentioned:
NCODA’s Immunotherapy Hub – A central resource offering clinical tools, SOP examples, and support for implementing therapies like bispecifics and antibody-drug conjugates.
Questions or looking to connect? Email the NCODA Clinical Team at clinical@ncoda.org